S3 cohort | XT cohort | Entire cohort | |||||||
PPM | Non-PPM | PPM | Non-PPM | PPM | Non-PPM | ||||
n=120 | n=700 | P value | n=115 | n=1199 | P value | n=235 | n=1899 | P value | |
LVEF, % | 60.0 (54.0–67.4) | 63.0 (54.6–67.0) | 0.16 | 60.3 (50.22–65.38) | 61.6 (53.0–66.95) | 0.16 | 60.0 (51.3–66.1) | 62.0 (53.4–67.0) | 0.07 |
Indexed EOA, cm2/m2 | 0.77 (0.71–0.82) | 1.17 (1.02–1.35) | <0.0001 | 0.79 (0.72–0.82) | 1.18 (1.03–1.36) | <0.0001 | 0.78 (0.72–0.82) | 1.18 (1.02–1.36) | <0.0001 |
Peak velocity, m/s | 2.6 (2.3–3.0) | 2.4 (2.1–2.6) | <0.0001 | 2.4 (2.1–2.8) | 2.2 (1.9–2.4) | <0.0001 | 2.5 (2.2–2.9) | 2.2 (2.0–2.5) | <0.0001 |
Paravalvular AR | 0.008 | 0.56 | 0.09 | ||||||
None/trace | 74 (61.7) | 529 (75.6) | 66 (57.4) | 731 (61.0) | 140 (59.6) | 1260 (66.4) | |||
Mild | 44 (36.7) | 163 (23.3) | 47 (40.9) | 456 (38.1) | 91 (38.7) | 619 (32.6) | |||
Moderate | 2 (1.7) | 8 (1.1) | 2 (1.7) | 11 (0.9) | 4 (1.7) | 19 (1.0) | |||
Severe | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
Paravalvular AR ≥mild | 46 (38.3) | 171 (24.4) | 0.002 | 49 (42.6) | 467 (39.0) | 0.48 | 95 (40.4) | 638 (33.6) | 0.04 |
Paravalvular AR ≥moderate | 2 (1.7) | 8 (1.1) | 0.65 | 2 (1.7) | 11 (0.9) | 0.32 | 4 (1.7) | 19 (1.0) | 0.31 |
MR ≥moderate | 11 (9.2) | 36 (5.1) | 0.09 | 10 (8.7) | 62 (5.2) | 0.13 | 21 (8.9) | 98 (5.2) | 0.02 |
Mean transprosthetic PG ≥20 mm Hg | 27 (22.5) | 26 (3.7) | <0.0001 | 9 (8.1) | 23 (2.0) | 0.001 | 36 (15.6) | 49 (2.6) | <0.0001 |
Mean transprosthetic PG ≥40 mm Hg | 1 (0.8) | 0 (0) | 0.15 | 0 (0.0) | 0 (0) | — | 1 (0.4) | 0 (0) | 0.11 |
Values are presented as the median (IQR), mean±SD, or n (%).
AR, aortic valve regurgitation; EOA, effective orifice area; LVEF, left ventricular ejection fraction; MR, mitral valve regurgitation; PG, pressure gradient; PPM, prosthesis–patient mismatch; S3, SAPIEN 3; XT, SAPIEN XT.